BlackRock’s Adial Pharmaceuticals ADIL Stock Holding History

BlackRock’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$778	Sell	304 -806	-73%	-$1.6K	﹤0.01%	5570
2026 Q1	$1.99K	Sell	1,110 -1	-0.1%	-$4	﹤0.01%	5519
2025 Q4	$6.11K	Hold	1,111	–	–	﹤0.01%	5329
2025 Q3	$9.82K	Hold	1,111	–	–	﹤0.01%	5214
2025 Q2	$8.39K	Hold	1,111	–	–	﹤0.01%	5232
2025 Q1	$17.6K	Hold	1,111	–	–	﹤0.01%	5107
2024 Q4	$28K	Hold	1,111	–	–	﹤0.01%	5051
2024 Q3	$27.7K	Hold	1,111	–	–	﹤0.01%	4899
2024 Q2	$31.9K	Buy	1,111 +805	+263%	+$30.4K	﹤0.01%	4937
2024 Q1	$10.2K	Hold	306	–	–	﹤0.01%	5086
2023 Q4	$14.2K	Hold	306	–	–	﹤0.01%	5119
2023 Q3	$21.2K	Sell	306 -5	-2%	-$590	﹤0.01%	5134
2023 Q2	$40.5K	Sell	311 -50	-14%	-$9.04K	﹤0.01%	5100
2023 Q1	$79K	Buy	361 +1	+0.3%	+$242	﹤0.01%	5017
2022 Q4	$48.3K	Buy	360 +2	+0.6%	+$350	﹤0.01%	5244
2022 Q3	$79K	Sell	358 -2	-0.6%	-$902	﹤0.01%	5244
2022 Q2	$301K	Sell	360 -1	-0.3%	-$906	﹤0.01%	4922
2022 Q1	$454K	Sell	361 -2	-0.6%	-$2.74K	﹤0.01%	4899
2021 Q4	$613K	Buy	363 +51	+16%	+$100K	﹤0.01%	4816
2021 Q3	$837K	Sell	312 -1	-0.3%	-$2.09K	﹤0.01%	4604
2021 Q2	$499K	Sell	313 -16	-5%	-$24.3K	﹤0.01%	4697
2021 Q1	$498K	Hold	329	–	–	﹤0.01%	4610
2020 Q4	$350K	Hold	329	–	–	﹤0.01%	4398
2020 Q3	$459K	Hold	329	–	–	﹤0.01%	4279
2020 Q2	$286K	Hold	329	–	–	﹤0.01%	4308
2020 Q1	$267K	Hold	329	–	–	﹤0.01%	4174
2019 Q4	$496K	Hold	329	–	–	﹤0.01%	4163
2019 Q3	$311K	Hold	329	–	–	﹤0.01%	4252
2019 Q2	$346K	Hold	329	–	–	﹤0.01%	4256
2019 Q1	$705K	Hold	329	–	–	﹤0.01%	4018
2018 Q4	$1.05M	Buy	+329	New	+$526K	﹤0.01%	3860

Other funds holding ADIL

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCM

Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock's ADIL Position: Q2 2026 in Review

BlackRock reduced its Adial Pharmaceuticals (ADIL) stake by 73% in Q2 2026, selling an estimated $1.6K and leaving 304 shares worth $778. The position accounts for ﹤0.01% of the portfolio, ranked #5570.

BlackRock first reported a position in ADIL in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.05M in Q4 2018. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

BlackRock held 304 shares of Adial Pharmaceuticals worth $778 as of Q2 2026.
BlackRock sold 806 Adial Pharmaceuticals shares in Q2 2026, an estimated $1.6K.
Adial Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5570 holding.
BlackRock first reported a position in Adial Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
BlackRock's Adial Pharmaceuticals position peaked at $1.05M in Q4 2018.
17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.